Treatment of uncomplicated gonorrhoea with single dose aztreonam

D T P EVANS,* A J R CROOKS,* C JONES,* R A HOLMAN,† AND S W PRICE†

From the Departments of *Genitourinary Medicine and †Medical Microbiology, Royal Infirmary, Cardiff

SUMMARY Infection with Neisseria gonorrhoeae was cleared in 61 men and 26 women at all sites (except in the pharynx of one male bisexual patient with urethral and pharyngeal gonorrhoea) after treatment with aztreonam as a single 1 g intramuscular injection. Aztreonam was well tolerated with no adverse effects. This monobactam antibiotic was effective against both penicillin sensitive and resistant strains.

Introduction

With the emergence of penicillinase producing Neisseria gonorrhoeae (PPNG) strains has come the need for β-lactamase stable compounds for treating gonorrhoea. Aztreonam, the first of a new class of β-lactam antibiotics, the monobactams, was developed specifically for treating infections due to aerobic Gram negative bacteria including the gonococcus.1,2 Aztreonam, given as a single 1 g intramuscular dose, has been shown to be effective in uncomplicated anogenital gonorrhoea, being effective against both penicillin sensitive and resistant strains in vitro.2 In vivo studies also show such efficacy.3,4 We undertook this study to confirm the efficiency of aztreonam in treating gonorrhoea in Cardiff.

Patients and methods

The study was open in design and included male and female patients with acute uncomplicated genital or anorectal gonorrhoea, or both. Verbal informed consent was obtained from all patients, and the protocol was approved by the local ethical committee.

PATIENTS

We excluded patients from the study if they were aged under 18 or over 75, had a history of an anaphylactic reaction or other serious reaction to penicillins or cephalosporins, were pregnant or breast feeding, had a condition that required treatment with an anti-infective agent other than the study drug, had a neutrophil count of less than 1 x 109/l, or had taken antibiotics, including metronidazole, in the previous 14 days or during treatment and follow up. (Concomitant local antifungal agents were permitted.) At entry to the study a routine clinical examination was carried out and clinical signs and symptoms recorded.

MICROBIOLOGICAL METHODS

Smears were taken from the urethra, cervix, rectum, or pharynx as appropriate and cultured on modified New York City medium to confirm gonococcal infection. Gram stained smears were examined in the clinic for the presence of Gram negative intracellular diplococci. A urine sample was obtained for urine analysis and culture. Production of β-lactamase was tested for by the acidimetric method. Isolates were also tested for susceptibility to penicillin, cefuroxime, spectinomycin, and aztreonam using the disc diffusion method.5

Patients were then treated with a single 1 dose of aztreonam injected into the gluteal muscle. They were asked to abstain from sexual intercourse and to attend follow up the next week (seven days) and one month (35 days) later. At follow up they were questioned about possible side effects and the tolerability of the injection. Cultures were taken from the urethra, cervix, and rectum of women at follow up.

Cultures were repeated at follow up visits to assess microbiological cure or failure. Patients who did not return for assessment within 21 days were excluded.
Treatment of uncomplicated gonorrhoea with single dose aztreonam

from analysis. Patients who had had sexual relations between the initial and follow up visits were excluded from analysis if the gonococcal infection was not eradicated, because of the possibility of reinfection.

Results

Of 102 patients enrolled in the study, 11 were excluded from analysis for the following reasons: six men because they had positive Gram films at entry, but subsequent culture was negative; four men and one woman because their cultures were still positive at follow up and they were known to have been reinjected.

This left a total of 91 evaluable patients for the study; 65 men and 26 women. Four of the men were homosexual and one was bisexual. The mean (SD) age of the patients was 24.5 (6.1) years. Four patients had concurrent infection with either Chlamydia trachomatis, Candida albicans, or Trichomonas vaginalis. The bisexual man, aged 25, had a sore throat by the seventh day after treatment, which proved to be due to pharyngeal gonorrhoea.

Table I shows the sites from which N gonorrhoeae was isolated, and the subsequent cure rates. Of the 91 strains, five of which were β-lactamase producers (PPNG). The minimum inhibitory concentration (MIC) of aztreonam for the PPNG strains was 0.4 mg/l. For non-PPNG strains the MICs ranged from 0.125 mg/l to 0.4 mg/l (table II). Of non-PPNG strains, 86.3% were sensitive to penicillin discs at a concentration of less than 0.06 mg/l. All strains (PPNG and non-PPNG) were sensitive to aztreonam 30 μg discs, spectinomycin 100 μg discs, and cefuroxime 30 μg discs.

Discussion

Aztreonam is the first of a new class of monocyclic β-lactam antibiotics, the monobactams. It was developed specifically for the treatment of Gram negative bacterial infections and is highly stable to chromosomal R plasmid mediated β-lactamase produced by aerobic Gram negative organisms.1 In contrast to recent cephalosporins, aztreonam does not induce β-lactamase production,2 which should therefore not be a major problem with this compound. Its range of activity in vitro toward Gram negative bacteria is comparable with that of the aminoglycosides and the third generation cephalosporins, and this has been confirmed in experimental Gram negative infections in animals.3

Aztreonam also differs from the penicillins and cephalosporins in its low allergenicity, which is important in the treatment of patients who have a history of hypersensitivity to penicillin.4 Aztreonam conjugated to human serum albumin does not cross react in vitro with human IgG and IgE anti-penicilloyl antibodies.5,6

Pharmacokinetic studies in man have shown that aztreonam has an elimination half life of 1.3–2 hours. It is widely distributed in body fluids and tissues and is eliminated primarily in the urine in an unchanged form. It is also secreted into the bile and is metabolised to a minor extent.7 After oral administration less than 1% is bioavailable, which means that aztreonam must be given intramuscularly.8

Table I: Sites of infection with Neisseria gonorrhoeae and cure rates

<table>
<thead>
<tr>
<th>Site</th>
<th>No of patients</th>
<th>Cure rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urethra</td>
<td>64</td>
<td>100</td>
</tr>
<tr>
<td>Rectum</td>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>Pharynx</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Women:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urethra</td>
<td>26</td>
<td>100</td>
</tr>
<tr>
<td>Cervix</td>
<td>26</td>
<td>100</td>
</tr>
<tr>
<td>Rectum</td>
<td>1</td>
<td>100</td>
</tr>
<tr>
<td>Pharynx</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

NB some patients were infected at more than one site.
Aztreonam has been shown to penetrate the cerebrospinal fluid, and is effective against syphilis in experimental animals.

The safety profile of aztreonam is similar to that of other β-lactam antibiotics, and the drug is well tolerated. With single dose treatment, six of 346 patients (1.7%) experienced adverse clinical effects. The most common reaction was nausea or vomiting, or both. No serious reactions have been reported.

In our study all patients were cleared of their gonococcal infection at all sites, except for the pharynx of one male bisexual patient. Aztreonam was well tolerated and had no adverse effects. This therefore confirms the efficiency and tolerability of aztreonam as a single intramuscular injection for treating uncomplicated gonorrhoea. Penicillinase producing gonococci are now common in some centres, and it may be necessary to routinely use a β-lactam stable antibiotic with the safety profile of a β-lactam agent, but with little or no cross sensitivity in patients allergic to penicillin or cephalosporin. Aztreonam promises to be such an antibiotic.

We thank E R Squibb and Sons, who supplied the aztreonam, and in particular Paul Woods (clinical trials manager at Squibb) for a critical review of the manuscript.

References